Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Hydroxyurea | Hydrea | 4.5. Interactions with other medicinal products | Lab tests interactions | Dec,2023 |
| Bupropion Hydrochloride; Naltrexone Hydrochloride | Contrave | 4.4 Special Warnings and Special Precautions for Use | Brugada pattern/syndrome | Dec,2023 |
| Valproate Sodium | Depakine | 4.6. Fertility, pregnancy and lactation, 5.3 Preclinical Safety Data | In utero exposure to valproate may result in hearing impairment or deafness and eye malformations. Reproductive and developmental toxicity have been reported in animal studies | Dec,2023 |
| Sotorasib | Lumykras | 4.2 Posology and method of administration , 4.5. Interactions with other medicinal products" | Interaction with omeprazole and Breast cancer resistance protein (BCRP) substrate | Dec,2023 |
| Pitavastatin | Livazo | "4.4 Special Warnings and Special Precautions for Use , 4.8 Undesirable effects" | Myasthenia gravis and Ocular myasthenia | Feb,2023 |
| Fluvastatin | Lescol XL | "4.4 Special Warnings and Special Precautions for Use , 4.8 Undesirable effects" | Myasthenia gravis and Ocular myasthenia | Feb,2023 |